Supernus Pharmaceuticals, a biopharmaceutical company specializing in central nervous system diseases, has announced that it will reveal its financial and business results for the third quarter of 2024 on November 4, 2024, after the market closes. The company will hold a conference call and webcast at 4:30 p.m. ET on the same day. During the call, Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will provide insights into the results and address any questions from participants.
Investors who wish to join the live webcast can do so through the company’s Investor Relations website. Pre-registration is available for participants, ensuring they receive a personalized dial-in number and conference code for easy access to the call. It is recommended to dial in 15 minutes before the scheduled start time to avoid any technical difficulties.
Following the live call, a replay will be accessible on the Company’s Investor Relations website for those who missed the initial broadcast. The webcast will remain available on the website for 60 days after the live call, providing ample time for interested individuals to catch up on the information shared.
Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system diseases. Their current portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. Additionally, they are working on a range of novel CNS product candidates for various conditions such as hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more details about Supernus Pharmaceuticals and their upcoming Q3 2024 financial results announcement, you can visit their official website at www.supernus.com. If you have any inquiries or need further information, you can reach out to Jack A. Khattar, President and CEO, or Timothy C. Dec, Senior Vice President, and CFO at Supernus Pharmaceuticals.
Investors seeking to participate in the Q3 2024 earnings call can pre-register on the company’s website to secure their spot and receive personalized access details. This proactive approach ensures a seamless experience during the live webcast and allows for easy participation in the question and answer session following the management’s remarks. By offering a replay of the call on their Investor Relations website, Supernus Pharmaceuticals ensures that stakeholders can access the information shared at their convenience for up to 60 days post-broadcast.
